HERCULES, Calif., Feb. 14 /PRNewswire-FirstCall/ -- Bio-Rad Laboratories, Inc. , a multinational manufacturer and distributor of life science research products and clinical diagnostics, has rescheduled its conference call to report financial results for the fourth quarter and year ended December 31, 2005 to Wednesday, February 22, after the close of the market. The company will discuss these results in a conference call scheduled for 2:00 p.m. PT (5:00 p.m. ET) that day.
The originally scheduled call on Thursday, February 16, 2006 was rescheduled as a result of Bio-Rad’s recent settlement agreement with Applied Biosystems and Roche Molecular Systems regarding core and real-time thermal cyclers. Since GAAP requires that financial impact of the litigation and settlement agreement be recorded in the fourth quarter 2005, Bio-Rad needs additional time to appropriately evaluate and record the impact of the settlement and allow time for its external auditors to audit these events in the year-end numbers. Bio-Rad anticipates the filing of its Form 10K to occur as scheduled.
Interested parties can access the call by dialing 866-825-3209 (in the U.S.), or 617-213-8061 (international), access number 61793659. The live web cast can be accessed at http://www.bio-rad.com . A replay of the call will be available at 888-286-8010 (in the U.S.), or 617-801-6888 (international), access number 98718856 for seven days following the call and the web cast can be accessed at http://www.bio-rad.com for 30 days.
Bio-Rad Laboratories, Inc. (www.bio-rad.com) is a multinational manufacturer and distributor of life science research products and clinical diagnostics. It is based in Hercules, California, and serves more than 70,000 research and industry customers worldwide through a network of more than 30 wholly owned subsidiary offices.
Various statements made within this press release may constitute “forward-looking statements” for the purposes of the Securities and Exchange Commission’s “safe harbor” provisions under the Private Securities Litigation Reform Act of 1995 and Rule 3b-6 under the Securities Exchange Act of 1934. The forward-looking statements contained herein involve risks and uncertainties that could cause results to differ materially from the Company’s expectation.
Bio-Rad Laboratories, Inc.
CONTACT: Christine Tsingos, Vice President and Chief Financial Officer, orRon Hutton, Treasurer, both of Bio-Rad Laboratories, Inc., +1-510-724-7000,or investor_relations@bio-rad.com
Web site: http://www.bio-rad.com/
